Mazdutide
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Innovent · Phase 2 · Completed · Enrollment 328
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| IBI362 high dose | n/r | n/r | n/r | n/r |
| IBI362 low dose | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r |
| IBI362 moderate dose | n/r | n/r | n/r | n/r |
| IBI362 extra high dose | n/r | n/r | n/r | n/r |
Not shown
- IBI362 high dose: endpoint not reported
- IBI362 low dose: endpoint not reported
- placebo: endpoint not reported
- IBI362 moderate dose: endpoint not reported
- IBI362 extra high dose: endpoint not reported